REGENERAR
Financiado
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATI...
The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need. The project REGENERAR aims to d...
The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need. The project REGENERAR aims to develop a non-viral delivery formulation up to TRL4 for the delivery of an epigenetic reprogramming formulation to reprogram glial cells into neurons. The in vitro safety and targeting of the formulation will be tested against glial cells and organotypic cortical slice cultures. Several routes of administrations will be tested to enhance the accumulation of the formulation in the brain. In addition, the in vivo safety, elimination, targeting and epigenetic reprogramming will be evaluated. In addition, toxicological studies will be performed in GLP conditions to evaluate both in vivo systemic and local (brain) effects of the formulation. The development of the non-viral formulation will take in account the contributes of key stakeholders in the area of gene editing, health institutions, patient associations, among others. A roadmap will be developed for upscaling innovation to higher TRL´s upon the end of the action.
ver más
Duración del proyecto: 52 meses
Fecha Inicio: 2023-10-06
Fecha Fin: 2028-02-29
Fecha Fin: 2028-02-29
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-06
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-PATHFINDEROPEN-01-01:
EIC Pathfinder Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
UNIVERSIDADE DE COIMBRA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
353.00K€ |
Participante
693.58K€ |
Participante